Plasma procalcitonin levels in chronic haemodialysis patients

Turkish Journal of Medical Sciences

Volumn 35, Issue 4, 2005, Pages 241-244

  Akbulut, Handan ^a   Çelik, Ilhami ^a   Özden, Mehmet ^a   Doǧukan, Ayhan ^a   Bulut, Vedat ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Haemodialysis; Procalcitonin

Indexed keywords

CORRELATION METHODS; DIALYSIS; HEALTH CARE; PROTEINS;

C-REACTIVE PROTEIN; HAEMODIALYSIS; PROCALCITONIN;

PATIENT TREATMENT;

C REACTIVE PROTEIN; PROCALCITONIN;

ADULT; ARTICLE; BACTERIAL INFECTION; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CALCITONIN BLOOD LEVEL; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY FAILURE; MALE; PATHOPHYSIOLOGY; TREATMENT OUTCOME; ULTRAFILTRATION; VENOUS BLOOD;

EID: 24344443643     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Mallioux LU, Belluci AG, Wilkes BM et al. Mortality in dialysis patients. Analysis of the causes of death. Am J Kidney Dis 18: 326-35, 1991.
2. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance haemodialysis patients. Kidney Int 54: 627-36, 1998.
3. Boucher BA. Procalcitonin: Clinical tool or laboratory curiosity? Crit Care Med 28: 1224-5, 2000.
4. Kuse ER, Langefeld I, Jaeger K et al. Procalcitonin in fever of unknown origin after liver transplantation: A variable to differentiate acute rejection from infection. Crit Care Med 28: 555-9, 2000.
5. Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med 26: 1193-1200, 2000.
6. Ortatatli M, Ozguven V, Sengul A. A new marker in diagnosis and follow up in sepsis and other severe infections: Procalcitonin. Flora 4: 151-5, 1999.
7. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-13, 1996.
8. Stevenson F. Inflammation and end stage renal disease: recent insights. Semin Dial 11: 119-23, 1998.
9. Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol 15: 297-301, 2002.
10. Level C, Chauveau P, Delmas Y et al. Procalcitonin: a new marker of inflammation in haemodialysis patients? Nephrol Dial Transplant 16: 980-6, 2001.
11. Dahaba AA, Rehak PH, List FW. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 29: 579-83, 2003.
12. Meisner M, Lohs T, Huettemann E et al. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 18: 79-87, 2001.
13. Nishikura T. The clearance of procalcitonin (PCT) during continuous veneous hemofiltration (CVVHD). Intensive Care Med 25: 1198-1201, 1999.
14. Herget-Rosenthal S, Marggraf G et al. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant 16: 975-9, 2001.
15. Dandona P, Nix D, Wilson MF et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79: 1605-8, 1994.
16. Oberhoffer M, Stonans I, Russwurm S. Procalcitonin expression in human peripheral blood monoclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 134: 49-55, 1999.
17. Schmidt M, Burchardi C, Sitter T, Held E et al. Procalcitonin in patients undergoing chronic haemodialysis. Nephron 84: 187-8, 2000.
18. Zimmermann J, Herrlinger S, Pruy A et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-58, 1999.